Related references
Note: Only part of the references are listed.The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder - A second multicenter, randomized, double-blind, placebo-controlled study
Ronald N. Marcus et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia:: A triple tracer PET study
David Mamo et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel
Gary Sullivan et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study
Robert M. Berman et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
A case series: Evaluation of the metabolic safety of aripiprazole
Marc De Hert et al.
SCHIZOPHRENIA BULLETIN (2007)
Medical comorbidity in women and men with schizophrenia: A population-based controlled study
Caroline P. Carney et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2006)
Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia
Bruce L. Lambert et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia
Andrew J. Cutler et al.
CNS SPECTRUMS (2006)
Attention-deficit hyperactivity disorder - bipolar comorbidity in children and adolescents
Gabriele Masi et al.
BIPOLAR DISORDERS (2006)
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study
Gary Sachs et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
The metabolic effects of antipsychotic medications
John W. Newcomer et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2006)
Psychiatric comorbidity in older adults with bipolar disorder
Martha Sajatovic et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2006)
Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study
Bun-Hee Lee et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2006)
Diabetic ketoacidosis associated with aripiprazole
CO Church et al.
DIABETIC MEDICINE (2005)
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania - Double-blind, randomised, comparative 12-week trial
E Vieta et al.
BRITISH JOURNAL OF PSYCHIATRY (2005)
The crossover approach to switching antipsychotics: What is the evidence?
G Remington et al.
SCHIZOPHRENIA RESEARCH (2005)
Aripiprazole in schizophrenia: consensus guidelines
MJ Travis et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2005)
Treatment guidelines for children and adolescents with bipolar disorder
RA Kowatch et al.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY (2005)
Switching between second-generation antipsychotics - Why and how?
M Edlinger et al.
CNS DRUGS (2005)
Dose response and dose equivalence of antipsychotics
JM Davis et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2004)
Consensus development conference on antipsychotic drugs and obesity and diabetes
DIABETES CARE (2004)
Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile
T Hirose et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2004)
The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: A retrospective chart review
DH Barzman et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2004)
In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function
S Jordan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
S Kasper et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2003)
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study
TA Pigott et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania
PE Keck et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology
DA Shapiro et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Antipsychotic-induced type 2 diabetes: Evidence from a large health plan database
F Gianfrancesco et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder
SG Potkin et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.
SR Marder et al.
SCHIZOPHRENIA RESEARCH (2003)
Risperidone-associated diabetes mellitus: A Pharmacovigilance Study
EA Koller et al.
PHARMACOTHERAPY (2003)
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
JM Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
KD Burris et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
S Jordan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Elevation of prolactin levels by atypical antipsychotics
P Turrone et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Managing antipsychotic-induced acute and chronic akathisia
CH Miller et al.
DRUG SAFETY (2000)
Share Paper
